December 2, 2013

Navidea Biopharmaceuticals to Host Analyst Science Day December 5, 2013 in New York City

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced it will hold an Analyst Science Day from 8:30 AM – 11:30 AM on Thursday, December 5, 2013.

Navidea CEO, Mark Pykett, VMD, PhD, will provide overviews on Lymphoseek® (technetium 99m tilmanocept) Injection and other Company programs and will be joined by members of the Navidea leadership team. Thomas Tulip, PhD, President and Chief Business Officer and David Pendleton, Vice President Marketing and New Product Planning will provide an analysis of the Lymphoseek US commercial launch and a discussion of commercial tracking metrics and trends; Frederick Cope, PhD, FACN, Senior Vice President and Chief Scientific Officer and Cornelia Reininger, MD, PhD, Senior Vice President and Chief Medical Officer will review the Company's two neuroimaging agents and Manocept™ program.

Several invited scientific and medical experts are also expected to participate, including:

Stephen Lai, MD, PhD
The University of Texas MD Anderson

Kenneth Williams, PhD
Boston College

Pedro Rosa-Neto, MD, PhD
McGill Centre for Studies in Aging

The event will be webcast live, and may be accessed by visiting the "Investors" section of the Company's website, www.navidea.com or this link: http://www.media-server.com/m/p/wotzk3cz. Interested parties unable to join the live call may access an archived version of the webcast on Navidea's website for 30 days following the event.

About Navidea Biopharmaceuticals Inc.

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing four radiopharmaceutical agent platforms – Lymphoseek® (technetium 99m tilmanocept) Injection, NAV4694, NAV5001 and RIGScan™ – to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. Navidea's first commercial agent, Lymphoseek, was approved by the FDA in March 2013. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company's pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com

Navidea Biopharmaceuticals
Brent Larson, 614-822-2330
Executive VP & CFO
or
Sharon Correia, 978-655-2686
Associate Director, Corporate Communications

Source: Navidea Biopharmaceuticals, Inc.